Delcath Systems to Host Quarterly Update Conference Call
December 30 2008 - 9:26AM
PR Newswire (US)
NEW YORK, Dec. 30 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH) announced today that the Company will host its
quarterly update conference call at 4:30 PM Eastern Time on
Thursday, January 22, 2009. Richard Taney, President and Chief
Executive Officer of Delcath Systems, will host the call. Mr. Taney
will discuss the progress of patient enrollment and the advancement
of clinical studies. A question and answer session will immediately
follow management's prepared remarks. (Logo:
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO) Joining
Mr. Taney on the call will be Mark Morrison, MD, PhD, Chief Medical
Officer; Jonathan Foltz, Executive Vice President; John Talarico,
Senior Vice President Regulatory Affairs and Quality Systems; and
Jason Rifkin, Senior Vice President Clinical Operations. Mr. Taney
will also introduce Barbra Keck, Delcath's recently hired
Controller. Ms. Keck will assume the responsibilities of Principal
Accounting Officer following the previously announced departure of
Delcath's Chief Financial Officer. Mr. Taney commented, "2008 was a
transformational year for Delcath. We expanded our pivotal Phase
III FDA trial from our base at the National Cancer Institute to 10
regionally diversified leading cancer hospitals and passed the
important milestone of 50% of patient enrollment. We have also
conserved cash resources and assembled a first class executive team
and Board of Directors to execute on our clinical and financial
milestones as we prepare for commercialization. I look forward to
speaking with the investment community in a few weeks to share our
excitement for 2009." The call will be available live and archived
via the Delcath website. In addition, the call can be accessed via
telephone; dial-in information will be provided a few days prior to
the call. About Delcath Systems, Inc. Delcath Systems, Inc. is a
medical technology company specializing in cancer treatment. The
Company is testing a proprietary, patented drug delivery system for
the treatment of liver cancers. Delcath's novel drug delivery
platform is testing the delivery of ultra-high doses of anti-cancer
drugs to the liver while preventing these high doses of drug from
entering the patient's bloodstream. The Company is currently
enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-eight
patents on a worldwide basis including the U.S., Europe, Asia and
Canada. For more information, please visit the Company's website at
http://www.delcath.com/. The Private Securities Litigation Reform
Act of 1995 provides a safe harbor for forward-looking statements
made by the Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our
ability to successfully complete Phase III clinical trials and
secure regulatory approval of our current or future drug-delivery
system and uncertainties regarding our ability to obtain financial
and other resources for any research, development and
commercialization activities. These factors, and others, are
discussed from time to time in our filings with the Securities and
Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. We undertake no obligation to publicly update or revise
these forward-looking statements to reflect events or circumstances
after the date they are made.
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO
http://photoarchive.ap.org/ DATASOURCE: Delcath Systems, Inc.
CONTACT: Company Contact: Richard Taney of Delcath Systems, Inc.,
+1-212-489-2100, ; or Public Relations Contact: Robin Wagge of
Rubenstein Associates, Inc., +1-212-843-8006, Web Site:
http://www.delcath.com/
Copyright